Skip to main content

Advertisement

SpringerLink
Log in

A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Women who receive adjuvant chemotherapy for breast cancer develop fatigue, and a subset reports cognitive impairment. Methylphenidate is reported to improve fatigue and to decrease cognitive impairment in other populations.

Materials and methods

Women were randomised early during their chemotherapy to receive d-methylphenidate (d-MPH), a form of methylphenidate, or an identical appearing placebo. All participants took placebo for one cycle to ensure compliance and then study medication until completion of chemotherapy. Subjects were assessed at baseline, end of chemotherapy and at ∼6 months follow-up with the High Sensitivity Cognitive Screen (HSCS) and the Hopkins Verbal Learning Test-Revised (HVLT-R). They also completed the self-report Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-F (F = fatigue) questionnaires, evaluating quality of life and fatigue.

Results

A total of 57 evaluable women were randomised: 29 to d-MPH and 28 to placebo; the study did not meet its accrual goal of 170 patients, mainly because women were reluctant to take additional medication in general and methylphenidate in particular. Groups were well matched for age (median, 50 years) and education. d-MPH and placebo were well tolerated. There were no significant differences between the randomised groups in classification of cognitive function by HSCS or in summed FACT-F fatigue scores (the primary endpoints of the study) at any of the assessments. There were also no differences in HLTV-R scores or quality of life.

Conclusions

This study is underpowered, but there are no trends to suggest that d-MPH, taken concurrently with adjuvant chemotherapy, improves quality of life or fatigue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long- term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493

    Article  PubMed  CAS  Google Scholar 

  2. Benedict RH, Zgaljardic DJ (1998) Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol 20:339–352

    Article  PubMed  CAS  Google Scholar 

  3. Berger AM (1998) Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 25:51–62

    PubMed  CAS  Google Scholar 

  4. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J (1988) Age-specific norms for the Mini-Mental State Exam. Neurology 38:1565–1568

    PubMed  CAS  Google Scholar 

  5. Bower JE, Ganz PA, Desmond KA et al (2006) Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106:751–758

    Article  PubMed  Google Scholar 

  6. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J (2001) A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 161:411–420

    Article  PubMed  CAS  Google Scholar 

  7. Brezden CB, Phillips KA, Abdolell M et al (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701

    PubMed  CAS  Google Scholar 

  8. Broeckel JA, Jacobsen PB, Horton J et al (1998) Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16:1689–1696

    PubMed  CAS  Google Scholar 

  9. Brown RT, Amler RW, Freeman WS et al (2005) Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 115:e749–757

    Article  PubMed  Google Scholar 

  10. Bruera E, Brenneis C, Paterson AH, MacDonald RN (1989) Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 4:3–6

    Article  PubMed  CAS  Google Scholar 

  11. Bruera E, Driver L, Barnes EA et al (2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21:4439–4443

    Article  PubMed  CAS  Google Scholar 

  12. Bruera E, Valero V, Driver L et al (2006) Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24:2073–2078

    Article  PubMed  CAS  Google Scholar 

  13. Bruera E, El Osta B, Valero V et al (2007) Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 25:3475–3481

    Article  PubMed  CAS  Google Scholar 

  14. Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579

    PubMed  CAS  Google Scholar 

  15. Fogel BS (1991) The high sensitivity cognitive screen. Int Psychogeriatr 3:273–288

    Article  PubMed  CAS  Google Scholar 

  16. Greene D, Nail LM, Fieler VK et al (1994) A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer. Cancer Pract 2:57–62

    PubMed  CAS  Google Scholar 

  17. Hinkin CH, Castellon SA, Hardy DJ et al (2001) Methylphenidate improves HIV-1-associated cognitive slowing. J Neuropsychiatry Clin Neurosci 13:248–254

    PubMed  CAS  Google Scholar 

  18. Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4:678–684

    PubMed  CAS  Google Scholar 

  19. Kukull WA, Larson EB, Teri L et al (1994) The mini-mental state examination score and the clinical diagnosis of dementia. J Clin Epidemiol 47:1061–1067

    Article  PubMed  CAS  Google Scholar 

  20. Lindley C, Vasa S, Sawyer WT, Winer EP (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16:1380–1387

    PubMed  CAS  Google Scholar 

  21. Macleod AD (1998) Methylphenidate in terminal depression. J Pain Symptom Manage 16:193–198

    Article  PubMed  CAS  Google Scholar 

  22. Mar Fan HG, Houede-Tchen N, Yi QL et al (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2 year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032

    Article  Google Scholar 

  23. Markes M, Brockow T, Resch KL (2006) Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev Oct 18(4):CD005001

    Google Scholar 

  24. McNeil C (2001) Cancer fatigue: one drug fails but more are in the pipeline. J Natl Cancer Inst 93:892–893

    Article  PubMed  CAS  Google Scholar 

  25. Meyers CA, Weitzner MA, Valentine AD, Levin VA (1998) Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522–2527

    PubMed  CAS  Google Scholar 

  26. O’Shaughnessy JA, Vukelja SJ, Holmes FA et al (2005) Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5:439–446

    Article  PubMed  CAS  Google Scholar 

  27. Roscoe JA, Morrow GR, Hickok JT et al (2005) Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89:243–249

    Article  PubMed  CAS  Google Scholar 

  28. Schagen SB, van Dam FS, Muller MJ et al (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650

    Article  PubMed  CAS  Google Scholar 

  29. Shapiro AM, Benedict RH, Schretlen D, Brandt J (1999) Construct and concurrent validity of the Hopkins verbal learning test-revised. Clin Neuropsychol 13:348–358

    PubMed  CAS  Google Scholar 

  30. Sitzia J, Huggins L (1998) Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract 6:13–21

    Article  PubMed  CAS  Google Scholar 

  31. Tchen N, Juffs HG, Downie FP et al (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183

    Article  PubMed  Google Scholar 

  32. Thompson SJ, Leigh L, Christensen R et al (2001) Immediate neurocognitive effects of methylphenidate on learning- impaired survivors of childhood cancer. J Clin Oncol 19:1802–1808

    PubMed  CAS  Google Scholar 

  33. van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218

    Article  PubMed  Google Scholar 

  34. Vardy J, Wong K, Yi QL et al (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14:1111–1118

    Article  PubMed  Google Scholar 

  35. Wefel JS, Lenzi R, Theriault RL et al (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299

    Article  PubMed  CAS  Google Scholar 

  36. Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology 4:61–66

    Article  Google Scholar 

  37. Wilwerding MB, Loprinzi CL, Mailliard JA et al (1995) A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 3:135–138

    Article  PubMed  CAS  Google Scholar 

  38. Yee JD, Berde CB (1994) Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 9:122–125

    Article  PubMed  CAS  Google Scholar 

  39. Yellen SB, Cella DF, Webster K et al (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63–74

    Article  PubMed  CAS  Google Scholar 

  40. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Canadian Breast Cancer Research Initiative (CBCRI). We thank Celgene Corporation for supplying d-MPH and matched placebo. The study protocol was developed at the ASCO/AACR Workshop, “Methods in Clinical Cancer Research”, 2001.

Author information

Authors and Affiliations

  1. Princess Margaret Hospital and University of Toronto, 610 University Ave, Suite 5-218, Toronto, Ontario, M5G 2M9, Canada

    Helen G. Mar Fan, Wei Xu, Irene Chemerynsky, Sharon Braganza & Ian F. Tannock

  2. Princess Alexandra Hospital, Brisbane, Australia

    Helen G. Mar Fan

  3. Toronto Sunnybrook Cancer Centre, Toronto, Ontario, Canada

    Mark Clemons & Henriette Breunis

  4. Princess Margaret Hospital, Toronto, Ontario, Canada

    Mark Clemons

Authors
  1. Helen G. Mar Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irene Chemerynsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henriette Breunis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sharon Braganza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ian F. Tannock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian F. Tannock.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mar Fan, H.G., Clemons, M., Xu, W. et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16, 577–583 (2008). https://doi.org/10.1007/s00520-007-0341-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-007-0341-9

Keywords

Search

Navigation